Pifithrin pft α

Manufactured by Merck Group

Sourced in United States

Pifithrin (PFT)-α is a lab equipment product manufactured by Merck Group. It is a chemical compound that functions as a reversible inhibitor of p53-mediated transactivation and apoptosis. The core function of Pifithrin (PFT)-α is to regulate cellular processes through the modulation of p53 activity, a key transcription factor involved in various cellular pathways.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using pifithrin pft α

Directed Differentiation of hPSCs into Pancreatic β-Cells

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Differentiation was initiated when hPSCs reached 80% confluence. We used two protocols to generate MPCs as described in Supplementary Table 1. We used our established protocol of Memon et al. [20 (link)–22 ] to generate MPCs (pancreatic progenitors). For further differentiation of MPCs into pancreatic β-cells, updated version (v8) of Pagliuca et al., was used [16 (link)]. mTeSR1 media was replaced with MCDB131 and/or DMEM/F12 (Thermo Fisher Scientific) supplemented with the stage-specific cytokines and growth factors (the detailed protocol and cytokines were described in Fig. 1A, Supplementary Table 1). p53 inhibitors, pifithrin (PFT)-α and PFT-μ (Sigma, USA), were added at two different concentrations (10 μM and 20 μM) for 4 days during stage 4 of differentiation. During stage 5, 20 μM PFT-μ were added daily.Fig. 1

Differentiation of hESCs into pancreatic progenitors and pancreatic β-cells. (A) Schematic diagram showing the differentiation protocols used to generate multipotent pancreatic progenitor cells (MPCs) and pancreatic β-cells. (B) Immunofluorescence analysis for the co-expression of PDX1 and NKX6.1 and glucagon (GCG) and insulin (INS) in hESC-derived MPCs and hESC-derived pancreatic β-cells. Scale bars = 50 μm

Aigha I.I, & Abdelalim E.M. (2023). p53 Inhibition in Pancreatic Progenitors Enhances the Differentiation of Human Pluripotent Stem Cells into Pancreatic β-Cells. Stem Cell Reviews and Reports, 19(4), 942-952.

+ Open protocol

+ Expand

Ovarian Cancer Cell Line Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two platinum-resistant human ovarian cancer cell lines OVCAR-3 (p53 mutant) and A2780/CP70 (p53 wild-type) were kindly provided by Dr. Jiang at West Virginia University. IOSE-364, a normal ovarian surface epithelial cell line, was a gift from Dr. Auersperg at University of British Columbia, Canada. All cells were cultured in RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine serum (FBS) (Invitrogen) at 37 °C in a humidified incubator with 5% CO₂. ChK, kindly provided by Dr. Cutler at the University of Mississippi, was prepared in dimethyl sulfoxide (DMSO) at 100 mM and stored at −20 °C. Cisplatin, pifithrin (PFT)-α and 2′,7′-dichlorofluorescein diacetate were purchased from Sigma-Aldrich. The primary antibodies against Bcl-xL, Bad, p21, phospho-p53 (ser15), p53, MDM2, phospho-ERK1/2, ERK1/2 (MK1) and GAPDH were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The primary antibodies against caspase-3, -8, and -9, Puma, Bax, Bcl-2, cyclin B1, phospho-cdc2 (Tyr 15), cdc2, Fas, Fas L, DR5, FADD, Phosphop38 MAPK (Thr180/Tyr182), p38 MAPK, Phospho-SAPK/JNK (Thr183/Tyr185) and SAPK/JNK were purchased from Cell Signaling Technology, Inc. (Danvers, MA).

Li B., Gao Y., Rankin G.O., Rojanasakul Y., Cutler S.J., Tu Y, & Chen Y.C. (2014). Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells. Cancer letters, 356(2 0 0), 418-433.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!